HIGHLIGHTS
- who: Soo-Youl Kim from the (UNIVERSITY) have published the research work: New Insights into Development of Transglutaminase 2 Inhibitors as Pharmaceutical Lead Compounds, in the Journal: (JOURNAL)
- what: Our theoretical picture of the molecular mechanism by which TGase 2 can catalyze cross-linking has developed over time (Figure 2).
SUMMARY
2018, 6, 87; 2 of 11 focus on targeting the active_site as an irreversible inhibitor. Cysteamine is known to target active_site cysteine residues and has been launched as a potential therapeutic for a broad range of disease indications including cystic . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.